Literature DB >> 233154

Muscarinic supersensitivity: a possible model for the sleep disturbance of primary depression?

J C Gillin, N Sitaram, W C Duncan.   

Abstract

The sleep changes induced in normal volunteers following the administration of scopolamine on 3 consecutive mornings resemble many of the abnormalities observed in the sleep of patients with primary depression: increased sleep latency and reduced rapid eye movement (REM) latency, total sleep time, and sleep efficiency. Furthermore, in a multivariate discriminant analysis--previously shown to distinguish the sleep records of depresed patients from those of normal controls and insomniac patients--the records from baseline nights were selected as normal and those after scopolamine as predominately depressed. Those observations suggest to us that muscarinic supersensitivity in normals may function as a pharmacological model for the sleep disturbances of depression.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 233154     DOI: 10.1016/0165-1781(79)90023-4

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  11 in total

Review 1.  [Psychopathological aspects of "raptus melancholicus"].

Authors:  R Erkwoh; G Huber
Journal:  Nervenarzt       Date:  2009-07       Impact factor: 1.214

Review 2.  Control of sleep and wakefulness.

Authors:  Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

3.  Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.

Authors:  Maura L Furey; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2006-10

4.  Biochemical pharmacology of paradoxical sleep.

Authors:  J M Gaillard
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

5.  Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder.

Authors:  D M Cannon; J K Klaver; S K Gandhi; G Solorio; S A Peck; K Erickson; N Akula; J Savitz; W C Eckelman; M L Furey; B J Sahakian; F J McMahon; W C Drevets
Journal:  Mol Psychiatry       Date:  2010-03-30       Impact factor: 15.992

Review 6.  Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.

Authors:  Wayne C Drevets; Carlos A Zarate; Maura L Furey
Journal:  Biol Psychiatry       Date:  2012-11-28       Impact factor: 13.382

7.  The anterior cingulate cortex may enhance inhibition of lateral prefrontal cortex via m2 cholinergic receptors at dual synaptic sites.

Authors:  Maria Medalla; Helen Barbas
Journal:  J Neurosci       Date:  2012-10-31       Impact factor: 6.167

8.  Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light.

Authors:  Jana Tchekalarova; Lidia Kortenska; Natasha Ivanova; Milena Atanasova; Pencho Marinov
Journal:  Psychopharmacology (Berl)       Date:  2019-11-13       Impact factor: 4.530

9.  A brief history of hypocretin/orexin and narcolepsy.

Authors:  J M Siegel; R Moore; T Thannickal; R Nienhuis
Journal:  Neuropsychopharmacology       Date:  2001-11       Impact factor: 7.853

Review 10.  Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression.

Authors:  Wayne C Drevets; Joseph L Price; Maura L Furey
Journal:  Brain Struct Funct       Date:  2008-08-13       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.